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Background. Human immunodeficiency virus (HIV)-infected, hepatitis C virus (HCV)-uninfected patients are
at risk for incident HCV infection, but little is known about screening practices for incident HCV among HIV-
infected individuals in HIV primary care clinics.
Methods. We used data from the Center for AIDS Research Network of Integrated Clinical Systems (CNICS) to
investigate historical trends in screening for incident HCV infection among HIV-infected patients who were HCV-
uninfected at enrollment in care. We used descriptive measures and Poisson regression to identify factors associated
with screening for HCV infection (using HCV antibody or RNA), performed temporal analyses to assess changes in
screening over time, and investigated the frequency with which elevated alanine aminotransferase (ALT) levels were
followed by diagnostic HCV testing.
Results. Among 17 090 patients registered at CNICS sites between 2000 and 2011, 14 534 (85%) received HCV
antibody screening within 3 months of enrolling in care, and 9077 met all of the inclusion criteria. Only 55.6%
ever received additional HCV screening. HCV screening increased over time, but not uniformly at all sites. Only
26.7% of first-time ALT elevations to >100 IU/L were followed up within 12 months by HCV antibody or RNA testing.
Conclusions. Although most HIV-infected patients were screened for prevalent HCV infection at enrollment in
care, only half who were HCV uninfected were screened again. Screening varied between sites, even when controlling
for demographics and risk behaviors. Patients with new ALT elevations to >100 IU/L were seldom assessed for incident
HCV infection. Guidelines are needed to help HIV providers know whom to screen, how frequently to screen, and
which screening test to use.
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Hepatitis C virus (HCV) coinfection is a leading cause
of hospitalization and death among human immunode-
ficiency virus (HIV)-infected individuals in the United
States and Europe [1–3]. Prevalent HCV infection is
commonly associated with a history of current or past
injection drug use (IDU) [4, 5]. Patients with a history
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of IDU who are not HCV infected remain at an increased risk
of developing incident HCV infection [6, 7]. Furthermore, over
the previous decade, cohort studies have demonstrated a rising
HCV incidence among HIV-infected men who have sex with
men (MSM) [7–20]. Most of these men with newly acquired
HCV infection reported no history of IDU—their risk appears
to be related to unprotected anal intercourse and noninjection
drug use, especially amphetamines [21].
In 2010, the European AIDS Treatment Network published
screening guidelines for incident HCV infection among HIV-
infected individuals, recommending testing twice a year using
serum alanine aminotransferase (ALT) and annually with
HCV antibody (Ab) among MSM engaging in unprotected
anal sex, as well as screening within 3 months of diagnosis of
a new sexually transmitted infection (STI) or IDU exposure
[22]. Mathematical modeling suggests that such a strategy
would extend life expectancy and be cost-effective [23]. In the
United States, STI guidelines published by the Centers for Dis-
ease Control and Prevention suggest considering annual HCV
Ab screening for individuals at high risk of infection [24], but
the definition of “high risk” is vague.
Understanding current practices, as well as the rate of uptake
of more routine screening for incident HCV infection, is essential
to inform the development of evidence-based HCV screening
strategies. We therefore used the Center for AIDS Research
(CFAR) Network of Integrated Clinical Systems (CNICS) to in-
vestigate current and historical patterns of screening for HCV
among HIV-infected individuals in the United States.
METHODS
Overview
We employed a retrospective cohort design to investigate the pro-
portion of patients uninfected with HCV at entry into HIV care
who ever received another HCVAb or HCV RNA test after their
negative baseline screening. We used bivariate and multivariate
analyses to identify patient-level factors associated with more fre-
quent screening, as well as factors associated with seroconversion.
We analyzed calendar time trends to assess the screening rate for
incident HCV after enrollment in care, and investigated the fre-
quency of HCV diagnostic testing, using either HCVAb or RNA,
following elevated values of serum ALT.
Data Source
The CNICS cohort includes >29 000 HIV-infected adults in clin-
ical care from 1995 to the present at 1 of 8 CFAR-funded sites
including Case Western Reserve University; University
of Alabama at Birmingham; University of California, San
Francisco; University of California, San Diego; University of
North Carolina at Chapel Hill; University of Washington;
Johns Hopkins University; and Fenway Health in Boston [25]
(available at: http://www.uab.edu/cnics). Seven CNICS sites con-
tributed data to this analysis. Institutional review boards at each
clinical site approved study protocols. For the purpose of result
reporting, we name the sites by identification number only.
The CNICS data repository captures comprehensive clinical
data, including standardized diagnoses, medications, laborato-
ry, risk factors for HIV transmission, and demographic infor-
mation collected through electronic health records and other
institutional data systems at each site. Between 2006 and
2010, sites instituted a clinical assessment where patients use
tablet computers to complete instruments measuring clinically
relevant patient-related outcomes (PROs), including drug use
and sexual risk behaviors every 4–6 months as part of routine
clinical care visits. Data quality assessment is conducted at the
sites prior to data transmission to the CNICS Data Management
Core (DMC). All data are fully reviewed prior to quarterly inte-
gration into the repository with any quality issues investigated
by the DMC. CNICS data elements relevant to this analysis in-
cluded patient demographics, risk factors for HIV transmission,
baseline CD4 cell count, history of AIDS-defining illnesses and
of non-HCV liver disease at enrollment in care, self-reported
amphetamine use and condom use, longitudinal laboratory re-
sults, and provider visit dates.
Participants and Screening Definitions
Participants for this analysis were ≥18 years of age who received
an HCV Ab test within 3 months of entry into HIV care at a
CNICS site (“baseline screening”). We limited the cohort to
those with documented negative baseline screening to exclude
those with prevalent HCV infection, as well as to exclude those
who did not undergo baseline screening and whose HCVAb test-
ing may reflect “catch-up” to guidelines for screening for preva-
lent HCVat enrollment in care. Participants were required to have
at least 12 months of follow-up time recorded in the dataset such
that they were exposed to the “risk” of being screened for incident
HCV. We defined all HCVAb tests and HCV RNA tests subse-
quent to the baseline HCVAb as “surveillance screening.”
Follow-up Time Definitions
Participants began contributing follow-up time at their first visit
in the dataset and continued to do so until either their last doc-
umented visit or laboratory test, whichever occurred last. For
time trend analyses, we defined 3 distinct calendar periods of
follow-up: 2000–2003, 2004–2007, and 2008–2011. We allowed
participants to contribute time to ≥1 follow-up period as appro-
priate using a time-updated analysis.
Analysis of HCV Screening
We calculated the rate of surveillance HCV screening at each
clinic site in each of the 3 calendar periods (defined as the
total number of HCV Abs obtained at the site divided by the
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total person-years of follow-up). Next, we calculated the rate of
surveillance screening for each individual (defined as the num-
ber of HCVAb obtained for a given individual/the individual’s
follow-up) and the median rate of screening stratified by clinic
site. We reported the proportion of patients at each site who had
received at least 1 surveillance screening test (Ab or RNA) at
fixed time intervals, while censoring patients who were lost to
follow-up at each time point.
Analysis of Response to Elevated ALT
For each participant, we identified the first ALT result (if any)
that was >40 IU/L (the upper limit of normal). We stratified
these first-observed elevated results by degree of elevation
(41–100 IU/L, 101–400 IU/L, >400 IU/L) and reported the per-
centage of time that a first-observed elevated ALT was followed
by diagnostic HCV Ab and RNA testing within 3, 6, and 12
months. If a participant had >1 ALT value >40 IU/L, we includ-
ed only the first value >40 IU/L, such that participants with
multiple elevated ALT levels were only considered once. We in-
cluded patients who had a baseline ALT >40 IU/L in the anal-
ysis, because if one is using ALT as a screening test for incident
HCV, the first-ever observation of an elevated ALT likely should
be followed with HCV diagnostic testing. As we included only
the first instance of elevated ALT, subsequent elevations were not
Table 1. Characteristics of Included Participants (N = 9077) and
Results of Multivariable Logistic and Poisson Regressions of
Patient-Level Factors Associated With Surveillance Hepatitis C





















<20 79 (0.9) Ref. Ref.
20–39 5111 (56.3) 0.88 (.53–1.45) 0.97 (.78–1.29)
40–59 3698 (40.7) 0.68 (.41–1.13) 0.86 (.68–1.07)
>60 189 (2.1) 0.55 (.31–1.00) 0.83 (.63–1.09)
Sex
Female 1421 (15.6) Ref. Ref.
Male 7656 (84.3) 1.09 (.92–1.29) 1.06 (.99–1.14)
Race
White 5176 (57.0) Ref. Ref.
Black 2791 (30.7) 1.11 (.99–1.26) 1.00 (.95–1.06)
Other 829 (9.1) 0.88 (.75–1.03) 0.96 (.90–1.03)
Unknown 281 (3.1)
Risk factor for HIV transmission
IDU 195 (2.1) Ref. Ref.
MSM 5778 (63.7) 0.59 (.42–.84) 0.80 (.70–.91)
MSM/IDU 504 (5.6) 1.13 (.75–1.71) 1.0 (.86–1.16)
Heterosexual 2277 (25.1) 0.513 (.36–.73) 0.76 (.66–.87)
Other 323 (3.56) 0.55 (.36–.73) 0.75 (.64–.89)
History of AIDS-defining illness at enrollment
Yes 3007 (33.1) 1.16 (1.04–1.31) 1.0 (.93–1.08)
No 6070 (66.9)
History of non-HCV liver disease
Yes 302 (3.3) 3.41 (2.51–4.63) 1.03 (.98–1.08)
No 8775 (96.7)
CD4 count at enrollment, cells/μL
<50 1205 (13.3) Ref. Ref.
50–99 562 (6.2) 0.86 (.42–.84) 0.91 (.82–1.00)
100–199 1060 (11.7) 0.93 (.76–1.13) 0.93 (.86–1.01)
200–349 1798 (19.8) 1.02 (.86–1.22) 0.97 (.90–1.04)
350–499 1783 (19.6) 1.08 (.90–1.29) 1.01 (.93–1.09)
≥500 2668 (29.4) 1.09 (.92–1.30) 1.00 (.93–1.08)
Missing 1 (0.01)
Patient-reported amphetamine use
No use 2235 (24.6) Ref. Ref.
Past use 1052 (11.6) 1.12 (.94–1.35) 1.0 (.93–1.07)
Current use 454 (5.0) 1.86 (1.42–2.44) 1.26 (1.14–1.38)












Patient-reported condom use for anal sex
No anal sex 1847 (20.4) Ref. Ref.
Always 601 (6.6) 1.14 (.92–1.42) 0.98 (.90–1.08)
Inconsistent 1116 (12.3) 1.31 (1.08–1.59) 1.09 (1.01–1.17)
Unknown 5531 (60.7) 1.40 (.69–2.87) 1.28 (1.01–1.64)
Patient-reported condom use for vaginal sex
No vaginal
sex
2964 (32.7) Ref. Ref.
Always 337 (3.7) 0.96 (.73–1.26) 0.97 (.87–1.09)
Inconsistent 241 (2.7) 1.31 (1.08–1.59) 1.24 (1.10–1.40)
Unknown 5535 (61.0) 1.40 (.69–2.87) 1.06 (.85–1.33)
Clinical site
1 1463 (16.1) Ref. Ref.
2 777 (8.6) 0.99 (.79–1.23) 1.24 (1.10–1.39)
3 1642 (18.1) 9.57 (7.88–11.61) 1.37 (1.24–1.50)
4 2235 (24.6) 4.31 (3.66–5.08) 2.08 (1.92–2.26)
5 980 (10.8) 1.86 (1.52–2.29) 1.07 (.97–1.19)
6 1254 (13.8) 0.86 (.72–1.04) 1.70 (1.54–1.87)
7 726 (8.0) 3.20 (2.58–3.97) 2.63 (2.42–2.85)
Abbreviations: CI, confidence interval; HCV, hepatitis C virus; HIV, human
immunodeficiency virus; IDU, injection drug use; MSM, men who have sex
with men; OR, odds ratio; PY, person-year; Ref., reference group.
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included in the analysis. In addition, because European guide-
lines recommend routine ALT screening only for HIV-infected
MSM [22], we repeated the analysis, including only participants
who reported MSM as their HIV transmission risk factor.
Statistical Methods
We used Pearson χ2 test, Student t test, and multivariate logistic
regression to investigate differences in patient-level characteris-
tics among those who received at least 1 surveillance HCV
screening and those who were screened at baseline only. Next,
we used χ2 test and logistic regression to compare patient-level
factors associated with seroconversion. We then used multivar-
iate Poisson regression, in which the number of surveillance
HCV screens was the outcome of interest with the time of fol-
low-up as an offset variable, to identify patient-level factors as-
sociated with more frequent surveillance screening. Covariates
in multivariable models included follow-up time contributed,
age, sex, race, history of AIDS-defining illness, history of non-
HCV liver disease, risk factors for HIV transmission (MSM,
IDU, MSM/IDU, heterosexual, or other), patient-reported am-
phetamine use and condom use, and clinic site. The “other” cat-
egory includes those who reported hemophilia/coagulation
disorders, receipt of blood transfusion, perinatal infection,
and healthcare workers. Because PROs were not available at
all sites throughout follow-up, we maintain “unknown” as a
separate category for all multivariable models. In addition, we
performed a sensitivity analysis limiting the cohort to those
who enrolled at CNICS sites during a time period when PROs
were being collected. Significance was set at P < .05 for all anal-
yses, and all statistical testing was conducted using Stata soft-
ware version 12.0 (StataCorp LP, College Station, Texas).
RESULTS
Cohort Characteristics
There were 17 090 CNICS participants ≥18 years of age seen at
least once during 2000–2011. Of these, 16 002 (93.6%) were
screened with HCV Ab at least once during follow-up, and
14 534 (85%) were screened within 3 months of their first clin-
ical visit (baseline screening). Among those who received base-
line screening, 2275 (15.6%) were excluded from this analysis
because they had reactive HCVAb, yielding 12 259 CNICS par-
ticipants with nonreactive HCVAb at baseline. Of those, 3182
were excluded because they had <1 year of follow-up. In total,
9077 participants met all inclusion criteria (Table 1). Partici-
pants included in the analysis were similar in demographic
characteristics to the general CNICS cohort.
Analysis of Surveillance HCV Screening
Among the 9077 participants included in the analysis, 5042
(55.6%) had at least 1 surveillance HCVAb or RNA screening
test. In bivariate analysis, the proportion of patients who ever
had surveillance HCVAb or RNA screening varied significantly
by clinical site, ranging from 35.3% at site 1 to 78.5% at site 3. In
multivariate logistic regression adjusting for time of follow-up,
participants who reported inconsistent condom use during anal
sex were significantly more likely to receive surveillance HCV
screening than those who reported not having anal sex (odds
ratio [OR] = 1.31 [95% confidence interval {CI}, 1.08–1.59];
Table 1). Similarly, those who reported current amphetamine
use were more likely to be screened than those who reported
no amphetamine use (OR = 1.86 [95% CI, 1.42–2.44]; Table 1).
Clinical traits associated with greater odds of HCV surveillance
screening included baseline history of AIDS-defining illness
Figure 1. Rates of surveillance screening for incident hepatitis C virus
(HCV) infection among human immunodeficiency virus-infected, HCV-
uninfected individuals enrolled at 7 Center for AIDS Research Network
of Integrated Clinical Systems sites from 2000 to 2011. A, Incidence of
screening for HCV across the entire clinic population (calculated as the
total number of HCV antibody [Ab] or RNA tests/total person-time of fol-
low-up). B, Cumulative incidence of first-time surveillance screening test
for incident HCV infection at each clinical site. In this analysis, participants
were censored when lost to follow-up.
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(OR = 1.16 [95% CI, 1.04–1.31]) and having a history of non-
HCV liver disease (OR = 3.41 [95% CI, 2.51–4.63]). Those
who reported MSM or heterosexual as their risk factor for
HIV transmission were less likely than IDU to ever receive sur-
veillance HCV screening (OR = 0.59 [95% CI, .42–.84] and
OR = 0.513 [95% CI, .36–.73], respectively). The clinical site
at which participants received care was a significant predictor
of the odds of receiving surveillance HCV screening and had
larger effect estimates than reported risk for HIV transmission.
The odds of ever receiving HCV surveillance at site 3 were 9.6
times greater (95% CI, 7.88–11.61) than those at site 1 (Table 1).
When we limited the cohort to those enrolled in sites collecting
PRO data, clinical site continued to have a larger effect on sur-
veillance screening than did patient risk behaviors.
Across the follow-up period, the rate of surveillance HCVAb
and RNA screening varied significantly by site, ranging from
0.14 to 0.52 screens per person-year. Surveillance screening in-
creased over time, but the rate of increase differed between sites
(Table 1; Figure 1A and 1B). In the most recent calendar period
(2008–2011), the screening rates ranged from 0.24 at site 1 to
0.63 at site 3. In multivariate analysis that controlled for patient
demographics, risk factors for HIV transmission, clinical char-
acteristics, drug use and sexual risk behaviors, clinical site, and
calendar time, the surveillance screening rate varied signifi-
cantly between sites (Table 1).
When we considered the median individual screening rate,
we observed similar trends. At the beginning of the follow-up
period, the median rate of screening at all sites was zero. Over
time, the median rate of screening increased at most sites, but
not all. Between 2008 and 2011, the median rate of screening
remained zero at sites 1 and 6, meaning that at least 50% of
the participants at those sites were never screened for HCV
after their negative baseline screen. At site 3, the site with the
highest rates of screening, the median rate of screening was
0.55, meaning that 50% of patients were screened for incident
HCV at least once every 2 years.
Additionally, the proportion who had received surveillance
screening at fixed time intervals had similar variation in screen-
ing between sites. For example, among those who were followed
for 60 months at site 3, 87% had received at least 1 surveillance
HCV test by month 60, whereas among those followed for
Table 2. Associations Between Clinical and Behavioral
Characteristics and Development of Incident Hepatitis C Virus
(HCV) Among HIV-Infected, HCV-Uninfected Participants, 2000–
2011 (n = 267)
Characteristic Odds Ratio (95% CI) P Value
Age, y
<20 Ref.
20–39 1.04 (.24–4.58) .96
40–59 0.74 (.17–3.27) .69
>60 0.64 (.10–4.30) .65
Sex
Male Ref.
Female 1.19 (.74–1.89) .47
Race
White Ref.
Black 1.12 (.80–1.56) .53
Other 0.88 (.59–1.33) .54
Risk factor for HIV transmission
IDU Ref.
MSM 0.25 (.15–.45) <.001
MSM/IDU 0.82 (.45–1.51) .42
Heterosexual 0.19 (.1–.34) <.001
Other 0.41 (.19–.88) .023
CD4 cell count, cells/μL
<50 Ref.
50–99 1.08 (.53–2.20) .83
100–199 1.59 (.91–2.76) .10
200–349 1.51 (.90–2.54) .12
350–499 0.91 (.52–1.59) .73
≥500 1.34 (.80–2.24) .26
History of AIDS-defining illness 1.00 (.74–1.36) .99
History of non-HCV liver disease 2.71 (1.72–4.28) <.001
Patient-reported amphetamine use
No use Ref.
Past use 1.86 (1.12–3.08) .02
Current use 3.59 (2.07–6.21) <.001
Unknown 1.59 (.70–3.59) .27
Patient-reported condom use for anal sex
No anal sex Ref.
Always 1.19 (.61–2.33) .61
Inconsistent 1.59 (.98–2.56) .06
Unknown 0.35 (.09–1.42) .14
Patient-reported condom use for vaginal sex
No vaginal sex Ref.
Always 0.50 (.15–1.67) .26
Inconsistent 1.85 (.93–3.67) .08
Unknown 3.75 (1.09–12.89) .04
Clinical site
1 Ref.
2 0.43 (.15–1.23) .12
3 1.74 (.95–3.17) .07
4 1.16 (.64–2.08) .63
5 0.98 (.47–2.01) .95
Table 2 continued.
Characteristic Odds Ratio (95% CI) P Value
6 1.63 (.86–3.08) .13
7 1.33 (.66–2.71) .43
Abbreviations: CI, confidence interval; HCV, hepatitis C virus; HIV, human
immunodeficiency virus; IDU, injection drug use; MSM, men who have sex
with men; Ref., reference group.
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60 months at site 1, 35% had been screened. When we restricted
the analysis to MSM only, we found rates similar to those ob-
served in the cohort as a whole and similar pattern in screening
trends over time. At sites 3, 5, and 7, rates of screening among
HIV-infected MSM increased substantially compared with
other sites (Figure 1B).
Analysis of Seroconversion and Factors Associated With
Seroconversion
Among the 5042 participants who had at least 1 surveillance
HCV screening test performed, 267 (5.3%) seroconverted.
The mean ALT level prior to positive HCV testing was 101.7
(95% CI, 82.8–120.8), and median ALT was 61.5 IU/L (inter-
quartile range, 45.5–77.6). Participants who seroconverted
were more likely to report past or current amphetamine use
(OR = 1.86 [95% CI, 1.12–3.08] for past use, and OR = 3.59
[95% CI, 2.07–6.21] for current use). Inconsistent condom
use (anal or vaginal sex) was associated with seroconversion,
but the finding did not meet the level of statistical significance.
Seropositivity was also higher among MSM/IDU than among
the MSM or heterosexual risk categories (OR = 0.82 [95% CI,
.45–1.51]; Table 2).
Analysis of Response to Elevated ALT Levels
There were 3731 first-time ALT results >40 IU/L (Table 3).
Among the entire cohort, 26.7% of ALT levels >100 IU/L and
20.3% of ALT >400 IU/L were followed with HCV Ab or
RNA testing within 12 months of the first-time elevated ALT
result. When we considered only elevated ALT results among
MSM, 28.1% of ALT elevations >100 IU/L and 18.0% of ALT
>400 IU/L were followed by diagnostic HCVAb testing within
12 months.
DISCUSSION
This analysis demonstrates that although the large majority of
HIV-infected patients in the United States are screened for
HCV at enrollment in care, among those who do not have prev-
alent infection at baseline, surveillance screening for incident
HCV infection varies substantially between clinical sites—
even among those who report high-risk characteristics such as
current amphetamine use and anal sex with inconsistent con-
dom use. In multivariate analysis, the site at which a subject re-
ceives care has a larger impact than HIV transmission risk
factors and PROs on both the odds of ever receiving surveil-
lance screening and the rate of surveillance screening. Although
some sites have increased the frequency of screening for HCV,
the rate of change over calendar time is variable. Furthermore,
fewer than one-third of ALT levels >100 IU/L are followed-up
with diagnostic HCVAb testing within 12 months of the elevat-
ed result.
Screening for incident HCV is variable across sites and im-
provement in frequency of screening is also variable, highlight-
ing a need for US-based guidelines to inform HIV practice.
Such guidelines exist for one-time screening for prevalent
HCV infection among HIV-infected patients [26], resulting in
>90% of participants receiving at least 1 HCVAb screening and
85% screened for HCV within 3 months of enrolling in care.
Although publishing a recommendation for frequent and rou-
tine HCV screening will not itself change clinical practice, doing
so would encourage providers to screen routinely and provide a
metric by which practices could measure their performance.
This analysis does not include processes of care at specific
sites that may have influenced the increase in screening rates,
and future studies to understand uptake, spread, and variability
in provider practice may help success of such guideline
implementation.
European HCV screening guidelines currently recommend
routine screening for incident HCV among HIV-infected
MSM using serum ALT every 6 months combined with HCV
Ab every 12 months [22]. The positivity threshold that should
trigger additional diagnostic testing, however, is not clear. ALT
is an attractive screening test of incident HCV, because current
antiretroviral therapy guidelines already recommend ALT mon-
itoring every 6 months to assess treatment toxicity [27]. Math-
ematical modeling studies suggest that such a strategy would
extend life expectancy and be cost-effective [23]. However,
our analysis demonstrates that among HIV-infected MSM,
fewer than one-third of first-time ALT values >100 IU/L were
followed up with diagnostic HCVAb or RNA testing. Thus, it
Table 3. Rates of Diagnostic Hepatitis C Virus (HCV) Antibody or
RNA Testing in Response to Elevated Alanine Aminotransferase
Levels Among All HIV-Infected, HCV-Uninfected Participants and
Among HIV-Infected, HCV-Uninfected Men Who Have Sex With
Men
Diagnostic HCV Ab or RNAWithin
ALT Value, Total
3 mo 6 mo 12 mo
IU/L No. No. % No. % No. %
All participants
41–100 3143 250 7.9 362 11.5 571 18.2
101–400 509 78 15.3 100 19.7 136 26.7
>400 79 12 15.2 13 16.5 16 20.3
Total 3731 340 9.1 475 12.7 723 19.4
MSM only
41–100 2294 179 7.8 268 11.7 432 18.8
101–400 360 60 16.7 73 20.3 101 28.1
>400 61 8 13.1 8 13.1 11 18.0
Total 2715 247 9.1 349 12.9 544 20.0
Abbreviations: Ab, antibody; ALT, alanine aminotransferase; HCV, hepatitis C
virus; MSM, men who have sex with men.
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appears that providers in the United States do not routinely use
ALT as a screening test for incident HCV.
Certainly, there are many clinical explanations for an elevated
ALT, and providers who know that their patient has a noninfec-
tious etiology for an elevated ALT would likely not follow every
elevated value with diagnostic HCV testing. We limited our
analysis, however, to only first-time ALT elevations, and still
found that less than one-third were followed with a diagnostic
evaluation for HCV infection. It is very unlikely that 70% of
first-time elevated ALT levels >100 IU/L were completely ex-
plained by other comorbidities. If US guidelines recommend
more frequent screening for HCV using ALT, future work will
need to define a clear threshold.
There are limitations to this analysis. First, residual con-
founding could obscure the fact that observed differences in
screening rates among clinical sites reflect differences in patient
populations, rather than practice variation based predominantly
on geography. We used patient-reported drug use and condom
use behaviors to control for differences in HCV risk; such self-
reported behaviors may be biased. In addition, because CNICS
data are extracted from medical records, it is possible that some
patients in the cohort received a portion of their care at a non-
CNICS center, resulting in incomplete outcomes data.
In summary, this analysis demonstrates that although most
HIV-infected patients are screened once for prevalent HCV in-
fection at entry into HIV care, significant practice variations re-
main in rates of screening for incident HCV. These differences
are not well explained by patient demographics or risk behaviors,
although patients who report IDU remain more likely to be
screened than MSM or heterosexual patients. Additionally,
those with new ALT elevations to >100 IU/L are unlikely to
have diagnostic testing for HCV. Therefore, opportunities exist
to improve outcomes; US-based national guidelines informing
whom to screen, how frequently to screen them, and what screen-
ing test to use are an important first step in this direction.
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